DNA Sequencing Gene Editing Synthetic Biology RNA Sequencing Pathogen Surveillance Next-Generation Sequencing Whole Genome Sequencing Plant Science DNA Research Phenotyping Single Cell Analysis Insect Behavior RNA Biology Research and Development Breeding Technologies Microbial Genomics Conservation Technology Proteomics mRNA Technology Metagenomics Transcriptomics Integrative Biology DNA Methylation Cancer Research Drug Development Cancer Genomics Clinical Data Crop Development Clinical Research Gene Expression Drug Discovery Genome Editing Sequencing Technology AI Applications Agricultural Science Research Institutions Single-Cell Sequencing Medical Applications Companies Biodiversity Clinical Genomics Craig J. Venter DNA Repair Mechanisms Crop Improvement Neoantigens Gene Therapy Genetic Variation
The stock-heavy offer would fold Personalis' NeXT Personal MRD test into Tempus' AI oncology platform pending shareholder and regulatory approval.